Entero Therapeutics Inc (ENTO)
2.74
+0.11
(+4.18%)
USD |
NASDAQ |
May 31, 16:00
2.75
+0.01
(+0.36%)
After-Hours: 20:00
Entero Therapeutics Research and Development Expense (Quarterly): 0.566M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.566M |
| December 31, 2023 | 1.307M |
| September 30, 2023 | 1.011M |
| June 30, 2023 | 1.353M |
| March 31, 2023 | 1.362M |
| December 31, 2022 | 0.1018M |
| September 30, 2022 | -7.294M |
| June 30, 2022 | 2.907M |
| March 31, 2022 | 4.976M |
| December 31, 2021 | 5.778M |
| September 30, 2021 | 24.38M |
| June 30, 2021 | 5.648M |
| March 31, 2021 | 2.516M |
| December 31, 2020 | 14.70M |
| September 30, 2020 | 1.796M |
| June 30, 2020 | 1.089M |
| March 31, 2020 | 1.549M |
| December 31, 2019 | 0.7528M |
| September 30, 2019 | 2.222M |
| Date | Value |
|---|---|
| June 30, 2019 | 2.876M |
| March 31, 2019 | 3.010M |
| December 31, 2018 | 1.999M |
| September 30, 2018 | 1.169M |
| June 30, 2018 | 0.9258M |
| March 31, 2018 | 1.678M |
| December 31, 2017 | 0.1512M |
| September 30, 2017 | 0.9667M |
| June 30, 2017 | 0.7434M |
| March 31, 2017 | 0.5341M |
| December 31, 2016 | 0.2256M |
| September 30, 2016 | 0.7443M |
| June 30, 2016 | 0.8407M |
| March 31, 2016 | 0.6856M |
| December 31, 2015 | -0.3364M |
| September 30, 2015 | 0.364M |
| June 30, 2015 | 1.062M |
| March 31, 2015 | 0.3088M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-7.294M
Minimum
Sep 2022
24.38M
Maximum
Sep 2021
3.480M
Average
1.672M
Median
Research and Development Expense (Quarterly) Benchmarks
| BioVie Inc | 5.700M |
| Jaguar Health Inc | 4.312M |
| Benitec Biopharma Inc | 2.566M |
| Immuneering Corp | 11.20M |
| NovaBay Pharmaceuticals Inc | 0.019M |